Vinpocetine: FDA Says It’s Not a Dietary Ingredient

Vinpocetine is not a lawful dietary ingredient in the United States. In September 2016 the FDA published a Federal Register notice setting out its tentative conclusion that vinpocetine does not meet the statutory definition of a dietary ingredient, because it is a synthetic compound rather than a constituent of a botanical, and because it was authorized for investigation as a new drug before it was marketed as a supplement. On 3 June 2019 the agency went further and advised women of childbearing age to avoid vinpocetine entirely, citing adverse reproductive effects including possible miscarriage and fetal harm. Products that contain it are, on FDA’s stated position, adulterated or misbranded.

Written by the Fog & Clarity editorial team · Published 13 July 2026 · Last updated 13 July 2026

The claim

Vinpocetine appears on labels as vinpocetine, as periwinkle extract, as Vinca minor extract, and occasionally as Intelectol. The marketing story is consistent wherever it shows up: it increases cerebral blood flow, it improves “brain oxygenation,” and therefore it sharpens memory and clears mental fog. It is usually presented as a plant compound with a long European clinical history, which makes it sound both natural and pharmaceutically serious at the same time.

Two parts of that framing are wrong before anyone gets to the efficacy question. Vinpocetine is not a plant constituent. It is a semi-synthetic derivative of vincamine, itself an alkaloid of lesser periwinkle, and the molecule that ends up in a capsule has been made in a factory rather than extracted from a leaf. That distinction is not pedantry — it is the exact basis on which FDA concluded the ingredient falls outside what a dietary supplement is legally permitted to contain.¹²

Where it came from

Vinpocetine has been prescribed in parts of Central and Eastern Europe under names such as Cavinton since the 1970s, mostly for cerebrovascular indications. That history is real, and it is the source of the ingredient’s aura of legitimacy in the US supplement market: a compound that a doctor in Budapest might prescribe reads, to an American shopper, as evidence that somebody serious once tested it.

What that history does not include is a body of modern, well-controlled evidence that vinpocetine improves cognition in healthy people. The Western literature is thin, and the trials that exist are mostly old, small, and of poor methodological quality. A Cochrane review of vinpocetine in acute ischaemic stroke concluded there was insufficient evidence to draw conclusions. For cognitive enhancement in people without a diagnosed condition, the evidence is effectively absent — not negative, not mixed, absent.

The path into US supplements ran around that gap rather than through it. The ingredient arrived on the strength of its foreign drug status, and it stayed because nobody was checking. That is the part FDA eventually addressed.

What the regulatory record actually says

Two federal actions matter here, and both are public documents you can read yourself rather than claims we are asking you to take on trust.

Date	Document	What it says
September 2016	Federal Register notice, Request for Comment on the Status of Vinpocetine	FDA’s tentative conclusion that vinpocetine does not meet the statutory definition of a dietary ingredient: it is synthetic, and it was authorized for investigation as a new drug before being marketed as a supplement.
3 June 2019	FDA safety advisory on vinpocetine in dietary supplements	Women who are pregnant or who could become pregnant should not take vinpocetine, citing adverse reproductive effects including possible miscarriage and fetal harm.
Standing position	FDA ingredient page, vinpocetine	FDA has maintained the 2016 position. Products containing vinpocetine are adulterated or misbranded on that basis.

The reproductive warning is the one that ought to end the conversation for a large share of the people who encounter this ingredient. It is not a theoretical concern extrapolated from a mechanism; it is a specific federal advisory naming a specific population.¹

⚠️ If you could become pregnant, do not take this

FDA’s June 2019 advisory tells women of childbearing age to avoid vinpocetine entirely, citing possible miscarriage and fetal harm. Vinpocetine also inhibits platelet aggregation, which matters if you take warfarin, apixaban, rivaroxaban, clopidogrel or aspirin, and it can add to the effect of blood-pressure medication. If you have been taking a product and only now realize what was in it, that is a conversation to have with your prescriber or pharmacist rather than a search engine.

The second problem: it turns up where it isn’t declared

A 2020 analysis in Neurology: Clinical Practice by Cohen and colleagues tested US-sold “cognitive enhancement” supplements and detected five unapproved drugs among them — omberacetam (noopept), aniracetam, phenibut, vinpocetine and picamilon. The drugs were frequently present at doses above pharmacological norms, and frequently either undeclared or mis-declared relative to the label.³ A separate published analysis documented the same pattern for piracetam in products sold as supplements.⁴

Read that carefully, because it changes what the ingredient means for a shopper. It is not only that some products openly list vinpocetine. It is that a product can contain it without saying so, and can contain more of it than a European prescribing leaflet would allow. A reader who avoids the ingredient by reading labels is doing the right thing and is still not fully protected.

FDA has issued warning letters to sellers in this category on exactly this basis, including to Peak Nootropics LLC (also trading as Advanced Nootropics) on 5 February 2019.⁵ The agency has taken the same position on phenibut, stating plainly that it does not meet the statutory definition of a dietary ingredient, with warning letters in April 2019 and a permanent injunction against one seller in June 2023.⁶ The pattern is consistent: several of the most heavily marketed “nootropic” ingredients are drugs that were never approved for this use in the US, sold under a regulatory framework that was never meant to hold them.

Why the claim persists

Four things keep vinpocetine in circulation, and none of them is evidence.

“Periwinkle extract” reads as botanical. On a label, the plant name does more persuasive work than the molecule ever could. It is the same trick as calling a synthetic ingredient “plant-derived” — technically traceable to a plant, chemically nothing of the sort.
Foreign drug status is borrowed as validation. “Prescribed in Europe” is used to imply an evidence base that the Western literature does not contain.
The FDA position is tentative in form and firm in practice. The 2016 notice was a request for comment. That procedural wording gets quoted by sellers as though the question were still open. FDA has maintained the position since.
Enforcement is complaint-driven and slow. A warning letter reaches one company. It does not clear a category.

There is a broader lesson in how the FTC has handled memory marketing. In January 2017 the FTC and the New York Attorney General sued the makers of Prevagen over memory and cognition claims for apoaequorin; in December 2024, after a jury trial, the US District Court for the Southern District of New York ordered the company to stop making those deceptive memory and cognitive-improvement claims.⁷⁸⁹ A claim being widely repeated, for many years, in expensive advertising, is not evidence that anyone checked it. We wrote about that case in detail in our piece on apoaequorin.

What to do instead

If you are currently taking a product that lists vinpocetine, the practical steps are short. Stop taking it, keep the bottle and the label, and tell your prescriber or pharmacist — particularly if you are pregnant, could become pregnant, take an anticoagulant or antiplatelet drug, or take medication for blood pressure. If you experienced anything you thought might be a side effect, that is worth reporting to FDA’s MedWatch programme; the adverse-event record is one of the few mechanisms that makes this category visible at all.

If you are shopping rather than stopping, the useful move is to learn the label patterns that predict a product like this. Vinpocetine almost never appears alone; it appears in long proprietary blends alongside other pharmacologically active ingredients at undisclosed doses. We keep a running list in nine ingredients that signal a bad brain supplement, and a broader argument about the category in the case against brain supplements.

And if the underlying problem is that your thinking feels slow or unreliable, an ingredient with no efficacy evidence and an active federal warning is the wrong place to start. Our brain fog section covers the situational causes with better evidence behind them, and the tier list is the honest ranking of what has human trials and what does not.

What would change our mind

Two things, and they are independent. On the regulatory question, a final FDA determination reversing the 2016 conclusion — or a court decision vacating it — would change vinpocetine’s legal status, and we would say so with a date stamp. On the efficacy question, a large, independently funded, placebo-controlled trial in healthy adults, with a pre-registered cognitive primary endpoint and a duration measured in months rather than days, would give us something to weigh. Neither exists today, and the reproductive-toxicity advisory would still stand in front of both.

Frequently asked questions

Is vinpocetine illegal to buy in the US?

It is not a controlled substance, and it is not illegal to possess. FDA’s position is that it cannot lawfully be sold as a dietary supplement, which makes products containing it adulterated or misbranded. Those are different questions, and the practical result is that the ingredient remains available while its legal footing is, on FDA’s stated view, absent.¹

Is periwinkle extract the same as vinpocetine?

Not exactly, and the gap is the point. Vinpocetine is a semi-synthetic derivative of vincamine, an alkaloid found in lesser periwinkle. Labels that say “periwinkle extract” may be describing a plant extract, or may be describing the synthetic molecule in botanical clothing. If a product lists periwinkle and makes cerebral blood flow claims, treat it as vinpocetine until the manufacturer proves otherwise.

I took it for a few months. Should I be worried?

We cannot answer that for you, and anyone who does without knowing your history is guessing. The specific groups FDA flagged are women who are or could become pregnant. The interaction concerns are anticoagulants, antiplatelet drugs and blood-pressure medication. Bring the bottle to your pharmacist — they can read the full label faster than you can, and that visit costs nothing.

Does vinpocetine at least increase cerebral blood flow?

Changes in a blood-flow measure are a mechanism, not an outcome. Across this whole field, compounds that reliably alter cerebral perfusion have repeatedly failed to produce measurable cognitive benefit in trials. A mechanism tells you what to test. It never substitutes for the test.

Why do “nootropic” retailers still sell it?

Because FDA enforcement in the supplement space is largely reactive, and a warning letter binds the company that receives it. The 2019 letter to Peak Nootropics LLC is public and specific.⁵ It did not, and could not, remove the ingredient from the market.

Sources

These statements have not been evaluated by the Food and Drug Administration. Nothing here is intended to diagnose, treat, cure or prevent any disease.

This article is information, not medical advice. Talk to a doctor or pharmacist about your own situation, especially if you take prescription medication.